Ajanta Pharma Delivers Strong Profit Growth, Margins Slip Slightly

reported a solid quarterly performance with net profit rising to Rs 267 crore, up 18.7 percent year on year from Rs 225 crore. Revenue jumped 21.5 percent to Rs 1,422 crore compared with Rs 1,170 crore, reflecting steady demand across key markets. EBITDA came in at Rs 333 crore, increasing 12.1 percent from Rs 297 crore. However, EBITDA margin softened to 23.4 percent versus 25.4 percent, indicating cost pressures. Despite the healthy earnings trajectory, the stock traded sideways yesterday, moving within a narrow range as investors weighed margin contraction against strong topline and profit growth in recent trading sessions. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.